Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | AOC1 | P19801 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958176 | 1.00 | GAA (0.46) | GAAALDH1A1MAPTKDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL1301715 | 0.98 | GAA (0.45) | GAAALDH1A1MAPTKDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL29956207 | 0.98 | GAA (0.45) | GAAALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL29957033 | 0.82 | ALDH1A1 (0.45) | GAAALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL1896645 | 0.82 | ALDH1A1 (0.45) | GAAALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL29628428 | 0.74 | SIRT3 (0.45) | GAATDP1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL248787 | 0.74 | SIRT3 (0.45) | GAATDP1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL28376434 | 0.74 | KDM4E (0.38) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL1129426 | 0.73 | LOXL2 (0.38) | LMNA | |
| Hydrochloric Acid SCHEMBL15953194 | 0.73 | SIRT3 (0.44) | GAATDP1CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| CN-103140490-A | Azaindazole compounds | BRISTOL MYERS SQUIBB CO | 2013-06-05 | — | — | CN | disclosed |
| EP-2593453-A1 | AZAINDAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8168802-B2 | Ring closing and related methods and intermediates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168802-B2 | Ring closing and related methods and intermediates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | CYP11B1, CYP11B2, CYP2F1 | GAA 1592/4885ALDH1A1 420/4885MAPT 3245/4885 |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | GAA 1323/4885ALDH1A1 143/4885MAPT 4827/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | GAA 1976/4885ALDH1A1 1189/4885MAPT 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.